Increased plasma levels of high mobility group box 1 in patients with acute liver failure

G. Oshima, M. Shinoda, M. Tanabe, H. Ebinuma, R. Nishiyama, K. Takano, S. Yamada, T. Miyasho, Y. Masugi, S. Matsuda, K. Suda, K. Fukunaga, K. Matsubara, T. Hibi, H. Yagi, T. Hayashida, Y. Yamagishi, H. Obara, O. Itano, H. TakeuchiS. Kawachi, H. Saito, T. Hibi, I. Maruyama, Y. Kitagawa

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background: High-mobility group box 1 (HMGB1) is a monocyte-derived late-acting inflammatory mediator, which is released in conditions such as shock, tissue injury and endotoxin-induced lethality. In this study, we determined the plasma and hepatic tissue levels of HMGB1 in patients with acute liver failure (ALF). Patients and Methods: We determined the plasma levels of HMGB1 and aspartate aminotransferase (AST) in 7 healthy volunteers (HVs), 40 patients with liver cirrhosis (LC), 37 patients with chronic hepatitis (CH), 18 patients with severe acute hepatitis (AH), and 14 patients with fulminant hepatitis (FH). The 14 patients with FH were divided into two subgroups depending upon the history of plasma exchange (PE) before their plasma sample collection. The hepatic levels of HMGB1 were measured in tissue samples from 3 patients with FH who underwent living-donor liver transplantation and from 3 healthy living donors. Hepatic tissue samples were also subjected to immunohistochemical examination for HMGB1. Results: The plasma levels of HMGB1 (ng/ml) were higher in patients with liver diseases, especially in FH patients with no history of PE, than in HVs (0.3 ± 0.3 in HVs, 4.0 ± 2.0 in LC, 5.2 ± 2.6 in CH, 8.6 ± 4.8 in severe AH, 7.8 ± 2.7 in FH with a history of PE, and 12.5 ± 2.6 in FH with no history of PE, p < 0.05 in each comparison). There was a strong and statistically significant relationship between the mean plasma HMGB1 level and the logarithm of the mean AST level (R = 0.900, p < 0.05). The hepatic tissue levels of HMGB1 (ng/mg tissue protein) were lower in patients with FH than in healthy donors (539 ± 116 in FH vs. 874 ± 81 in healthy donors, p < 0.05). Immunohistochemical staining for HMGB1 was strong and clear in the nuclei of hepatocytes in liver sections from healthy donors, but little staining in either nuclei or cytoplasm was evident in specimens from patients with FH. Conclusion: We confirmed that plasma HMGB1 levels were increased in patients with ALF. Based on a comparison between HMGB1 contents in normal and ALF livers, it is very likely that HMGB1 is released from injured liver tissue.

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalEuropean Surgical Research
Issue number3
Publication statusPublished - 2012 Jun
Externally publishedYes


  • Acute liver failure
  • Fulminant hepatitis
  • High-mobility group box 1
  • Human
  • Liver transplantation

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Increased plasma levels of high mobility group box 1 in patients with acute liver failure'. Together they form a unique fingerprint.

Cite this